to Content
Header Image

Mag. Dr. Peter L. TURECEK Senior Director, Global Preclinical Research and Development, Baxter Innovations GmbH, Vienna


1980 Laboratory Assistant, Polymer Laboratory, Reichhold Chemie GmbH., Vienna
1982 Laboratory Assistant, Dept. of Radiopharmaceuticals, Institute of Chemistry, Österreichisches Forschungszentrum, Seibersdorf
1985-1988 Technician, Institute of Biochemistry, University of Vienna
1986-1989 Consultant for R&D Projects for MAGINDAG, Steirische Magnesit Industrie AG, Vienna and Research Biotechnology, Chemie Holding AG, Linz
1988-1989 Assistant Professor, Institute of Biochemistry, University of Vienna
1989-1990 Research Assistant, Dept. of Microbiology and Molecular Biology, Biomedical Research Center, IMMUNO AG, Orth
1991 Head, Laboratory of Recombinant Blood Factors, Biomedical Research Center, IMMUNO AG, Orth
1991-1992 Deputy Head, Dept. of Biochemical Research on Coagulation and Fibrinolysis, IMMUNO AG, Vienna
1992-1995 Head, Dept. of Biochemical Research on Haemostasis and Thrombolysis, IMMUNO AG, Vienna
since 1996 Legal Permission for Animal Experiments (Tierversuchsleiter gem. Österr. Tierversuchsgesetz 1988)
1996-1999 Head, Dept. of Process Monitoring Coagulation, Production Blood-Plasma Derivatives, Österreichisches Institut für Hämoderivate GesmbH, Vienna
1997-1999 Head, Depts. Product & Process Development Coagulation and Pharmaceutical Technology, Global R&D Plasma, BAXTER/HYLAND-IMMUNO, Vienna
since 1998 Habilitation für Pharmakologie und Toxikologie, University of Vienna
2000-2001 Member Diagnostics Management Team, Research & Development Therapeutic Proteins, Hyland Immuno Division, Baxter Healthcare, BAXTER AG, Vienna
2001-2005 Director Global Preclinical R&D and Product Development, BioScience Division, Baxter Healthcare, BAXTER AG, Vienna


EDQM-European Pharmacopoeia Commission - Permanent Specialist
Group of Experts Nr. 6B on Human Blood and Blood Products
American Society of Hematology (ASH)
Österreichische Gesellschaft für Molekulare Biowissenschaften und Biotechnologie(ÖGMBT)
Protein Society


Turecek, PL ( Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor. J Thromb Haemost, 2009
Turecek, PL ( Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy. Transfusion, 1959-77
Turecek, PL ( In vivo inhibition of low density lipoprotein receptor-related protein improves survival of factor VIII in the absence of von Willebrand factor. Blood, 2000
Turecek, PL ( Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease. Blood, 1999


Baxter Technical Awards (29 Awards), 1998-2008